With Progress against TB in Jeopardy, New and Improved Tools Are More Urgent than Ever
NEW YORK (October 14, 2020)—The World Health Organization’s Global Tuberculosis (TB) Report 2020 confirms that efforts to track and treat TB
Featured News
One Year Since U.S. Approval, Accelerating Access to New TB Therapy
PRETORIA — Today marks the one year anniversary of the US FDA’s approval of pretomanid as part of the BPaL
Dr. Mel Spigelman Named in Fast Company’s Annual List of the Most Creative People in Business
NEW YORK (August 4, 2020)—Fast Company today announced its 11th annual list of the Most Creative People in Business, honoring a diverse
TB Alliance Announces European Commission Authorisation of New Treatment for Highly Drug-Resistant Tuberculosis
Pretomanid, developed by the non-profit TB Alliance, has received EU marketing authorisation in combination regimen with bedaquiline and linezolid in
Mylan Secures DCGI Approval in India for Pretomanid, a Treatment for Highly Drug-Resistant Forms of Tuberculosis
Pretomanid is only the third new anti-tuberculosis (TB) drug developed specifically for drug-resistant forms of the disease to be approved
TB Alliance Commercialization Partner, Mylan, Launches Named Patient Access Program for New Highly Resistant TB Treatment
The NPAP is designed for patients in countries where regulatory approval or other access mechanisms for pretomanid are not yet
With One and a Half Million People Dying from TB Every Year, It’s Time to Accelerate Progress
The public health progress in the World Health Organization’s Global Tuberculosis (TB) Report 2019 this year can be found in
FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis
NEW YORK (August 14, 2019)—Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S.